ReviewClinical & translational immunology2014
EV71 vaccine, an invaluable gift for children.
Review in Clinical & translational immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial.Human vaccines & immunotherapeutics · 2016Trial
- A human intestinal organoid derived from fetal human colon cells model for studying enteroviral pathogenesis.Virulence · 2025Article
- A lethal juvenile mouse model for the evaluation of antiviral reagents against coxsackievirus A4.iScience · 2025Article
- Article
- Changing Epidemiology of Hand, Foot, and Mouth Disease Causative Agents and Contributing Factors.The American journal of tropical medicine and hygiene · 2024Review
- Anti-α-glucosidase, Anti-proliferative and Anti-enterovirus 71 Activity of Secondary Metabolites Identified from Grifola Frondosa.Plant foods for human nutrition (Dordrecht, Netherlands) · 2023Article
- Article
- Comparative analysis of the molecular mechanism of resistance to vapendavir across a panel of picornavirus species.Antiviral research · 2021Article
- Epidemiological characteristics of hand, foot, and mouth disease in Yunnan Province, China, 2008-2019.BMC infectious diseases · 2021Article
- Transcriptome analysis following enterovirus 71 and coxsackievirus A16 infection in respiratory epithelial cells.Archives of virology · 2020Article
- Recent advances of enterovirus 71Virology journal · 2020Review
- Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71.Nature communications · 2020Article
- Enterovirus 71 Infection Shapes Host T Cell Receptor Repertoire and Presumably Expands VP1-Specific TCRβ CDR3 Cluster.Pathogens (Basel, Switzerland) · 2020Article
- Comprehensive analysis of differential expression profiles via transcriptome sequencing in SH-SY5Y cells infected with CV-A16.PloS one · 2020Article
- Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid.PLoS pathogens · 2019Article
- Endophilin-A2-mediated endocytic pathway is critical for enterovirus 71 entry into caco-2 cells.Emerging microbes & infections · 2019Article
- A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5.Emerging microbes & infections · 2018Article
- Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo.Human vaccines & immunotherapeutics · 2018Article
- Prohibitin plays a critical role in Enterovirus 71 neuropathogenesis.PLoS pathogens · 2018Article
- Potential of small-molecule fungal metabolites in antiviral chemotherapy.Antiviral chemistry & chemotherapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterovirus 71 (EV71) is a major pathogen for severe hand, foot and mouth disease (HFMD). Development of vaccines against EV71 would be the most effective approach to prevent the EV71 outbreak. Research and development (R&D) of EV71 vaccine was carried out in several Asian countries. Currently three companies in mainland China have completed Phase III clinical trials of inactivated EV71 whole-virus vaccines, whereas the other two companies have completed Phase I clinical trials separately in Taiwan and in Singapore. Results from those clinical trials have indicated high safety and immunogenicity of EV71 vaccine. Protective efficacies were over 90% on EV71-associated HFMD and over 80% on other EV71-associated diseases. In this paper, we summarize the results from three EV71 vaccine Phase III clinical trials and discuss the challenges of incorporating EV71 vaccine into Expanded Program on Immunization (EPI) in countries with EV71 epidemics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.